Table of Contents Author Guidelines Submit a Manuscript
Emergency Medicine International
Volume 2014, Article ID 935474, 9 pages
http://dx.doi.org/10.1155/2014/935474
Review Article

Rivaroxaban and Hemostasis in Emergency Care

Institute for Transfusion Medicine, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

Received 28 November 2013; Accepted 14 January 2014; Published 20 February 2014

Academic Editor: Rade B. Vukmir

Copyright © 2014 Jürgen Koscielny and Edita Rutkauskaite. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, and F. Misselwitz, “The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor,” Nature Reviews Drug Discovery, vol. 10, no. 1, pp. 61–75, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Xarelto, “Summary of Product Characteristics,” 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
  3. D. Kubitz, M. Becka, A. Roth, and W. Mueck, “Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects,” Current Medical Research and Opinion, vol. 24, no. 10, pp. 2757–2765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf, “Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects,” European Journal of Clinical Pharmacology, vol. 61, no. 12, pp. 873–880, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Lang, C. Freudenberger, and C. Weinz, “In vitro metabolism of rivaroxaban, an oral, direct factor xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans,” Drug Metabolism and Disposition, vol. 37, no. 5, pp. 1046–1055, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang, “Metabolism and excretion of rivaroxaban, an oral, direct factor xa inhibitor, in rats, dogs, and humans,” Drug Metabolism and Disposition, vol. 37, no. 5, pp. 1056–1064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. Xarelto, “Prescribing Information,” 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202439s008lbl.pdf.
  8. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing, “Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor,” Clinical Pharmacology and Therapeutics, vol. 78, no. 4, pp. 412–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. G. G. Turpie, M. R. Lassen, B. I. Eriksson et al., “Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies,” Thrombosis and Haemostasis, vol. 105, no. 3, pp. 444–453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. The EINSTEIN Investigators, “Oral rivaroxaban for symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 363, no. 26, pp. 2499–2510, 2010. View at Publisher · View at Google Scholar
  11. The EINSTEIN–PE Investigators, “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism,” The New England Journal of Medicine, vol. 366, no. 14, pp. 1287–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Mega, E. Braunwald, S. D. Wiviott et al., “Rivaroxaban in patients with a recent acute coronary syndrome,” The New England Journal of Medicine, vol. 366, no. 1, pp. 9–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Lindhoff-Last, M. M. Samama, T. L. Ortel, J. I. Weitz, and T. E. Spiro, “Assays for measuring rivaroxaban: their suitability and limitations,” Therapeutic Drug Monitoring, vol. 32, no. 6, pp. 673–679, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Sarode, T. J. Milling Jr, M. A. Refaai et al., “Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study,” Circulation, vol. 128, pp. 1234–1243, 2013. View at Publisher · View at Google Scholar
  16. N. Khorsand, N. J. Veeger, R. M. van Hest, P. F. Ypma, J. Heidt, and K. Meijer, “An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies,” Haematologica, vol. 97, no. 10, pp. 1501–1506, 2012. View at Publisher · View at Google Scholar
  17. T. Desmettre, A. E. Dubart, G. Capellier et al., “Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008,” Thrombosis Research, vol. 130, no. 3, pp. e178–e183, 2012. View at Publisher · View at Google Scholar
  18. A. Hillarp, F. Baghaei, I. F. Blixter et al., “Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays,” Journal of Thrombosis and Haemostasis, vol. 9, no. 1, pp. 133–139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Baglin, D. Keeling, and S. Kitchen, “Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British committee for standards in haematology,” The British Journal of Haematology, vol. 159, no. 4, pp. 427–429, 2012. View at Publisher · View at Google Scholar
  20. M. M. Samama and C. Guinet, “Laboratory assessment of new anticoagulants,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 5, pp. 761–772, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Mueck, B. I. Eriksson, K. A. Bauer et al., “Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery,” Clinical Pharmacokinetics, vol. 47, no. 3, pp. 203–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Mani, C. Hesse, G. Stratmann, and E. Lindhoff-Last, “Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time,” Thrombosis and Haemostasis, vol. 106, no. 1, pp. 156–164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Haas, A. G. G. Turpie, M. R. Lassen et al., “Prothrombin time and bleeding events in patients undergoing total hip or knee replacement surgery receiving 10 mg rivaroxaban,” Blood (ASH Annual Meeting Abstracts), vol. 114, no. 22, abstract 2099, 2009. View at Google Scholar
  24. M. M. Samama, G. Contant, T. E. Spiro et al., “Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls,” Thrombosis and Haemostasis, vol. 107, no. 2, pp. 379–387, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Mani, G. Rohde, G. Stratmann et al., “Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin,” Thrombosis and Haemostasis, vol. 108, no. 1, pp. 191–198, 2012. View at Publisher · View at Google Scholar
  26. D. Kubitza, M. Becka, W. Mueck et al., “Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor,” The British Journal of Clinical Pharmacology, vol. 70, no. 5, pp. 703–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Kubitza, A. Roth, M. Becka et al., “Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor,” The British Journal of Clinical Pharmacology, vol. 76, no. 1, pp. 89–98, 2013. View at Publisher · View at Google Scholar
  28. D. Kubitza, M. Becka, A. Roth, and W. Mueck, “The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor,” Journal of Clinical Pharmacology, vol. 53, no. 3, pp. 249–255, 2013. View at Publisher · View at Google Scholar
  29. Eliquis, “Summary of Product Characteristics,” 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.
  30. Pradaxa, “Summary of Product Characteristics,” 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
  31. A. G. G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas, “Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor,” Thrombosis and Haemostasis, vol. 108, no. 5, pp. 876–886, 2012. View at Publisher · View at Google Scholar
  32. M. P. Donadini, W. Ageno, and J. D. Douketis, “Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach,” Drugs, vol. 72, no. 15, pp. 1965–1975, 2012. View at Publisher · View at Google Scholar
  33. D. M. Siegal and M. A. Crowther, “Acute management of bleeding in patients on novel oral anticoagulants,” European Heart Journal, vol. 34, no. 7, pp. 489–498, 2013. View at Publisher · View at Google Scholar
  34. E. Brem, A. Koyfman, and M. Foran, “Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians,” Journal of Emergency Medicine, vol. 45, no. 1, pp. 143–149, 2013. View at Publisher · View at Google Scholar
  35. The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board (Bundesärztekammer), “Chapter 7. Procoagulators. Cross-sectional guidelines for therapy with blood components and plasma derivatives,” Transfusion Medicine and Hemotherapy, vol. 36, no. 6, pp. 419–436, 2009. View at Google Scholar
  36. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. US Food and Drug Administration, “FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding,” 2013.
  38. A. Gruber, U. M. Marzec, U. Buetehorn, S. Hanson, and E. Perzborn, “Potential of activated prothrombin complex concentrate and activated Factor VII to reverse the anticoagulant effects of rivaroxaban in primates,” Blood (ASH Annual Meeting Abstracts), vol. 112, no. 11, abstract 3825, 2008. View at Google Scholar
  39. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Crackowski, and G. Pernod, “Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers,” Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217–224, 2012. View at Publisher · View at Google Scholar
  40. A. Godier, A. Miclot, B. Le Bonniec et al., “Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model,” Anesthesiology, vol. 116, no. 1, pp. 94–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Schulman and M. A. Crowther, “How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch,” Blood, vol. 119, no. 13, pp. 3016–3023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Kaatz, P. A. Kouides, D. A. Garcia et al., “Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors,” The American Journal of Hematology, vol. 87, supplement 1, pp. S141–S145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Sørensen, D. R. Spahn, P. Innerhofer, M. Spannagl, and R. Rossaint, “Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity,” Critical Care, vol. 15, no. 1, p. 201, 2011. View at Google Scholar · View at Scopus
  44. C. C. Hsia, I. H. Chin-Yee, and V. C. McAlister, “Use of recombinant activated factor vii in patients without hemophilia: a meta-analysis of randomized control trials,” Annals of Surgery, vol. 248, no. 1, pp. 61–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. Baxter Healthcare Corporation, “Thrombotic and thromboembolic events following infusion of FEIBA VH or FEIBA NF,” 2010, http://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/ucm221755.pdf.
  46. S. B. Rosenfeld, K. K. Watkinson, B. H. Thompson, D. E. Macfarlane, and S. R. Lentz, “Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient,” Thrombosis and Haemostasis, vol. 87, no. 5, pp. 925–926, 2002. View at Google Scholar · View at Scopus
  47. K. A. Bauer, “Reversal of antithrombotic agents,” The American Journal of Hematology, vol. 87, supplement 1, pp. S119–S126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Koscielny, J. Beyer-Westendorf, C. von Heymann et al., “Risk of bleeding and haemorrhagic complication with rivaroxaban—periprocedural management of haemostasis,” Hamostaseologie, vol. 32, no. 4, pp. 287–293, 2012. View at Publisher · View at Google Scholar
  49. G. Lu, F. R. DeGuzman, S. J. Hollenbach et al., “A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,” Nature Medicine, vol. 19, no. 4, pp. 446–451, 2013. View at Publisher · View at Google Scholar
  50. B. Laulicht, S. Bakhru, X. Jiang et al., “Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977,” Journal of Thrombosis and Haemostasis, vol. 11, supplement 2, abstract AS 47.1, 2013. View at Google Scholar